Skip to the page

Data / Form D filings / Autobahn Therapeutics, Inc.

Autobahn Therapeutics, Inc.: Form D filing

Autobahn Therapeutics, Inc., a biotechnology company in San Diego, CA, filed a Form D with the SEC in 2024. The latest, on August 1, 2024, reports $100.8 million sold of a $120 million offering to 22 investors.

SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.

Company details from the filing

Address
9880 CAMPUS POINT DRIVE, SUITE 370, San Diego, CA, 92121
Phone
(858) 257-3418
Industry
Biotechnology
Entity type
Corporation
Incorporated in
Delaware
Revenue range
Decline to Disclose
Exemptions claimed
Rule 506(b)
SEC identifier (CIK)
1815098

Form D filings

FiledTypeOfferingSoldRemainingInvestorsFirst saleFiling
Aug 1, 2024New notice$120,000,000$100,825,289$19,174,71122Jun 20, 2024sec.gov

Executive officers and directors named in the filing

NameRoleNote in the filing
Uwe J SchoenbeckDirector
John BorkholderExecutive Officer
Kristina BurowDirector
Thomas CahillDirector
Timothy AndersonDirector
Philip J DeSouzaDirector
Benjamin CravattDirector
Scott GiacobelloDirector
Kevin FinneyExecutive Officer, Director
Bonnie J van WilgenburgDirector

Other biotechnology companies in California that filed recently

Every Form D from the week of Jul 29, 2024 · All recent filings in California · All recent Biotechnology filings

Read from SEC EDGAR. Amount sold is what Autobahn Therapeutics, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.